XORTX Therapeutics Inc.

Contributing Author

Recent Articles by XORTX Therapeutics Inc.

Sep-10	XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO XRTX XRTX +10.43% GlobeNewswire
Sep-08	XORTX Re-Engages Investor Relations Program XRTX XRTX -5.35% GlobeNewswire
Aug-28	XORTX Announces Termination and Postponement of Investor Relations Program XRTX GlobeNewswire
Jul-31	XORTX Announces Director Resignation XRTX GlobeNewswire
Jul-29	XORTX Appoints New Director XRTX GlobeNewswire
Jun-15	XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO XRTX GlobeNewswire
Jun-12	XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange XRTX GlobeNewswire
May-19	XORTX Announces Closing of US$5 Million Public Offering XRTX -10.77% GlobeNewswire
May-14	XORTX Announces US$5 Million Public Offering XRTX -14.10% GlobeNewswire
Apr-21	XORTX Meets Nasdaq Continued Listing Requirements XRTX +19.56% GlobeNewswire
Apr-13	XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset XRTX -11.24% GlobeNewswire
Apr-01	XORTX Confirms Effective Date of Share Consolidation XRTX GlobeNewswire
Mar-26	XORTX Announces Results of Annual and Special Meeting of Shareholders XRTX -9.69% XRTX +9.88% GlobeNewswire
Mar-26	XORTX Announces Change of Effective Date of Share Consolidation XRTX -9.69% XRTX +9.88% GlobeNewswire
Mar-25	XORTX Announces Share Consolidation XRTX GlobeNewswire
Mar-24	XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting XRTX GlobeNewswire
Mar-18	XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders XRTX +6.45% GlobeNewswire
Mar-13	XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation XRTX -10.89% GlobeNewswire
Mar-05	XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders XRTX +7.78% GlobeNewswire
Feb-04	XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems XRTX XRTX -17.71% GlobeNewswire
Dec-31	XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update XRTX GlobeNewswire
Oct-29	XORTX Announces Closing of US$1.1 Million Registered Direct Offering XRTX GlobeNewswire
Oct-21	XORTX Announces Pricing of US$1.1 Million Registered Direct Offering XRTX GlobeNewswire
Oct-20	XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency XRTX GlobeNewswire
Oct-20	XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency XRTX -31.82% GlobeNewswire
Oct-17	XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems XRTX +29.41% GlobeNewswire
Sep-04	Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10 XRTX GlobeNewswire
Sep-03	XORTX Initiates IND Preparation for XORLO in Gout Program XRTX GlobeNewswire
Aug-08	XORTX Completes USD $114,500 Private Placement XRTX GlobeNewswire
Aug-07	XORTX Provides Corporate Update and Planned Activities for 2025 / 2026 XRTX +5.41% GlobeNewswire
Jul-31	XORTX Announces USD $114,500 Private Placement XRTX GlobeNewswire
Jul-22	XORTX Completes Non-Brokered Private Placement of Units XRTX XRTX -5.13% GlobeNewswire
Jun-26	XORTX Announces USD $925,000 Private Placement XRTX GlobeNewswire
May-19	XORTX Announces USD $3 Million Offering XRTX -14.02% GlobeNewswire

XORTX Therapeutics Inc.

Recent Articles by XORTX Therapeutics Inc.

Upgrade your Finviz experience